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Following recent revisions to the United States Centers for Medicare and Medicaid 
Services (CMS) Sepsis and Septic Shock Early Management Bundle (SEP-1) reporting 
requirement, the Infectious Diseases Society of America (IDSA) led a group of invested 
stakeholder organizations to develop a position paper of recommended revisions to further 
improve SEP-1. The goals of these recommendations from IDSA were primarily to improve the 
balance between early and aggressive treatment of life-threatening infections and antibiotic 
overuse. Specifically, these recommendations sought to enhance SEP-1 by focusing it as an 
evidence-based mandate only for the populations where evidence was the strongest and, 
secondarily, to limit unnecessary antibiotic exposure for patients without true infection but 
presenting with sepsis-mimicking syndromes.  Prior to publication of the guidance document, 
IDSA engaged the Society of Infectious Diseases Pharmacists (SIDP) by including a 
representative on the working group (EH) and provided an opportunity for SIDP to review and 
comment on these recommendations with an opportunity for endorsement. Per SIDP policy the 
IDSA recommendations were forwarded to the SIDP Guidelines Committee and Board of 
Directors to review and provide comment.  After extensive review and discussion, SIDP 
endorsed the recommended revisions from IDSA on the new SEP-1 reporting requirement.  In 
this Insights from SIDP, we highlight the main points of the IDSA position statement on 
recommended revisions to SEP-1 and offer suggestions to further clarify and strengthen the 
recommendations.  We emphasize SIDP’s perspective regarding opportunities for improved 
clarity and best practices toward patient care and antimicrobial use in this setting, as well as 
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The Society of Infectious Diseases Pharmacists agrees that the revisions suggested by 
IDSA are important improvements to the SEP-1 measure, and readers are encouraged to 
review the entire recommendation and rationale1.  Important highlights of the recommendations 
from IDSA are as follows.  First, IDSA emphasized that the current SEP-1 measures combine 
the entities of septic shock and sepsis without shock to address in the urgency for immediate 
antibiotic administration.  However, compared to septic shock, sepsis without shock requires 
alternative management strategies and has dramatically different outcomes. Thus, consolidating 
these two separate syndromes into one metric is not appropriate. This is illustrated in the 
references that accompany the IDSA recommendation, which demonstrate the change in risk-
benefit ratio for rapid antibiotic administration within these two entities. The Society of Infectious 
Diseases Pharmacists believes the current evidence supports timely administration of antibiotics 
in patients with severe sepsis as an urgent priority and that stewardship programs should 
prioritize minimizing time to appropriate therapy in these patients as well. However, since 
severe sepsis is a more nebulous definition and there are many syndromes that mimic this 
presentation, we agree this metric is unsuitable for a core measure bundle.  The second key 
statement from the IDSA is the recommendation that obtaining blood cultures before antibiotics 
should remain part of SEP-1. Although SIDP recognizes there may be potential downstream 
consequences of having to expedite blood culture collection before antibiotic administration 
(including potential contamination and processing issues), we agree that this recommendation is 
backed by sound scientific evidence to improve appropriate pathogen-directed therapy.  In 
addition, microbiologic testing is critical for antimicrobial stewardship programs to inform 
antibiotic optimization, either escalation or de-escalation, and to identify the optimal duration of 
therapy. Therefore, we believe the risk of negative consequences associated with obtaining a 
culture are outweighed by the benefits of directed therapy. An additional laboratory-based 
recommendation in the IDSA document advocates for removal of lactate measurements from 
SEP-1. The IDSA document clearly describes the lack of evidence for using lactate as an 
appropriate marker to initiate antibiotic therapy and otherwise guide management of septic 
shock.  
The other three recommendations from the IDSA are interrelated. The first states the 
need to more clearly define time zero in patients with shock based on clear and reproducible 
objective clinical data. The next two focus on administration strategies and recommend that the 
window for administration of antimicrobials from time zero be narrowed from 3 hours to 1 hour, 
and that SEP-1 should require hospitals to report the time interval between when antibiotics 
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Although SIDP agrees with the critical importance of these definitions and management 
strategies to optimize patient care, we emphasize additional areas of consideration with these 
recommendations in our commentary below.  
As stated, the IDSA recommends that the interval from septic shock time zero to 
initiation of broad-spectrum antibiotics should be 1 hour or less. Although we agree with the 
clinical benefit of this timing, SIDP has significant concerns with this timing being used as a 
quality metric as currently framed in the IDSA document. Although IDSA recommends septic 
shock time zero be clearly defined and reproducible, the recommendation is currently not paired 
with a defined time zero. Although the IDSA suggests potential time zero definitions, SIDP feels 
an appropriate time zero must be defined simultaneously with a change in antibiotic timing 
recommendations. Should time zero remain unchanged but the timing of administration be 
reduced, haste to administer antibiotics to meet this metric could result in an unintentional rise in 
antibiotic overuse. Furthermore, without careful consideration for time zero, practical 
considerations might make compliance with the measure impossible for certain institutions. This 
would include, but is not limited to, issues such as the inability to achieve rapid vascular access 
and provider burden in hospitals with multiple emergent patients.  These logistic issues can 
easily push antibiotic administration beyond this 1-hour window. In situations with diagnostic 
uncertainty, this delay becomes increasingly more likely.  
In order to overcome these challenges, SIDP advocates for a definition of time zero that 
is immediately evident to the treating clinicians at the point-of-care, which, ideally, could trigger 
an electronic medical record notification or other means of communication to identify the need to 
administer antibiotics under the SEP-1 measure.   The Society of Infectious Diseases 
Pharmacists believes the most practical and rational suggestion for time zero is to define this as 
the time of initiation of vasopressors. This time point could be easily abstracted from an 
electronic medical record and typically coincides with persistent hypotension following an 
adequate fluid challenge.  In the absence of such a clearly defined time zero that assures the 
ability to provide antimicrobials immediately, SIDP asserts that the original 3-hour goal, or even 
2 hours depending on institution type and/or resources, would be a more realistic goal for 
antibiotic administration for a quality metric.  
In addition to a consensus time zero, IDSA recommends that in patients with septic 
shock, SEP-1 should require hospitals to report “antibiotic delivery time”, defined as the time 
interval between when antibiotics are first ordered and when they are administered.  The 
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administration in order to facilitate the best possible clinical outcomes in patients with septic 
shock.  While this concept is laudable, SIDP is concerned that requiring hospitals to report this 
time interval could possibly lead to an easily manipulated quality metric. This could, in turn, 
further promote inappropriate ordering of standard antibiotic(s) that are readily and quickly 
available in emergency departments or general floor medicine cabinets. Such practice would 
counteract the message of thoughtful empiric antibiotic selection currently advocated by 
antimicrobial stewardship programs and could exacerbate inappropriate antibiotic use. In 
addition, reporting of time intervals between antibiotic orders and drug administration disregards 
potentially legitimate reasons for relative delays such as, but not limited to, allergy verification, 
assessment of antimicrobial spectrum relative to prior cultures, performance of diagnostic 
testing in venues that preclude antibiotic administration, and drug preparation and delivery.  
Nevertheless, SIDP recognizes the importance of prompt antibiotic administration in order to 
facilitate best possible clinical outcomes in patients with septic shock. Rather than implementing 
required reporting of this time interval, SIDP recommends specifically calling on hospital 
pharmacies to increase accountability for the drug distribution process from order verification to 
delivery to patient bedside. Furthermore, SIDP sees this as an opportunity for pharmacy 
operations to contribute in a directly measurable way in order to improve patient care without 
the need for an additional reporting requirement.
In addition to these specific comments on the recommendations from IDSA, SIDP also 
recommends general improvements in broad-spectrum antibiotic administration in patients with 
septic shock. Although septic shock may be caused by a variety of bacterial pathogens, the 
greatest proportion of sepsis episodes and sepsis-related mortality are attributable to gram-
negative bacteria2. Therefore, a broad-spectrum β-lactam empirically targeting gram-negative 
and gram-positive pathogens is the backbone of treatment in the absence of compelling 
arguments against their use (e.g., multiple true allergies, unusual resistance patterns). 
Accordingly, SIDP recommends that a broad-spectrum β-lactam or appropriate alternative 
therapy be administered as the first component of a potential multidrug antibiotic regimen for 
septic shock and, furthermore, that administration of this agent serve as the index time for 
initiation of antibiotics. Combination antimicrobial therapy targeting other select pathogens (e.g., 
methicillin-resistant Staphylococcus aureus, anaerobes, or fungi) are often used appropriately in 
patients with septic shock but should not be considered in “time to initiation” for SEP-1 due to 
their longer infusion times and the essentiality of β-lactam therapy.  In addition, SIDP 
recommends the term “delivery” not be used when recommending that broad-spectrum 
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refer to delivery of the antibiotic from the pharmacy, initiation of administration, or completion of 
the intravenous infusion. Therefore, SIDP instead recommends consistent use of the term 
“initiation” and that this term should refer exclusively to the start of intravenous antibiotic 
infusion, such as “antibiotic initiation time.”  
In summary, SIDP supports the recommendations provided by IDSA on the SEP-1 CMS 
Sepsis Quality Measure. The Society of Infectious Diseases Pharmacists also strongly 
advocates for clarification and/or further consideration of several key issues within the 
recommendations in order to more effectively operationalize the revisions within the existing 
framework of institutional workflow and patient care. Similar to IDSA, we strongly recommend 
core measures should be founded on strong evidence-based principles to improve the quality, 
delivery, and outcomes of care.  Finally, though not the focus of this document, SIDP believes it 
will be of utmost importance that changes to SEP-1 be paired with extensive education about 
the importance of timing of antibiotic administration. The Society of Infectious Diseases 
Pharmacists appreciates the opportunity to review and endorse these important 
recommendations and will continue to collaborate with IDSA to improve patient care and 
antimicrobial use.   
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